Outlook of IL-6 signaling blockade for COVID-19 pneumonia

被引：0
作者：
Misato Hashizume
机构：
[1] Chugai Pharmaceutical Co.,
[2] Ltd.,undefined
来源：
Inflammation and Regeneration | / 40卷
关键词：
Interleukin-6; COVID-19 pneumonia; Cytokine release syndrome; Tocilizumab; Sarilumab; Siltuximab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
In this review article, it is highlighted the implications of pleiotropic functions of interleukin-6 (IL-6) for one of the therapeutic options targeting for COVID-19. Moreover, it is discussed how real-world data and trials with IL-6 signaling blockade will be crucial in informing the development of new treatment for COVID-19 pneumonia.
引用
收藏
相关论文
共 135 条
[1]  
Kishimoto T(1973)Regulation of antibody response in vitro. VII. Enhancing soluble factors for IgG and IgE antibody response J Immunol. 111 1194-1205
[2]  
Ishizaka K(2020)Translating IL-6 biology into effective treatments Nat Rev Rheumatol. 16 335-345
[3]  
Choy EH(2015)Tocilizumab, a humanized anti-IL-6R antibody, as an emerging therapeutic option for rheumatoid arthritis: molecular and cellular mechanistic insights Int Rev Immunol. 34 265-279
[4]  
De Benedetti F(2018)Interleukin-6: designing specific therapeutics for a complex cytokine Nat Rev Drug Discov. 17 395-412
[5]  
Takeuchi T(2012)Atherogenic effects of TNF-α and IL-6 via up-regulation of scavenger receptors Cytokine. 58 424-430
[6]  
Hashizume M(2010)Anti-inflammatory mechanism of tocilizumab, a humanized anti-IL-6R antibody: effect on the expression of chemokine and adhesion molecule Rheumatol Int. 30 309-315
[7]  
John MR(2016)Effect of IL-6 Receptor Blockade on High-Sensitivity Troponin T and NT-proBNP in Rheumatoid Arthritis Atherosclerosis. 254 167-171
[8]  
Kishimoto T(2019)Interleukin-5, interleukin-6, interferon induced protein-10, procalcitonin and C-reactive protein among mechanically ventilated severe community-acquired viral and bacterial pneumonia patients Cytokine. 113 272-276
[9]  
Hashizume M(2019)The Other Side of CAR T-Cell Therapy: Cytokine Release Syndrome, Neurologic Toxicity, and Financial Burden Am Soc Clin Oncol Educ Book. 39 433-444
[10]  
Tan SL(2018)FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome Oncologist. 23 943-947
12345678910